“NALPAC” A NON-COMPARATIVE RANDOMIZED PHASE 2 STUDY, EVALUATING THE EFFICACY OF 5-FU + NALIRI AND 5-FU + NALIRINOX FOR METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), PROGRESSIVE AFTER GEMCITABINE-ABRAXANE OR GEMCITABINE MONOTHERAPY.
RecruitingCTIS2024-516336-97-00
Groupe Belge D'Oncologie DigestiveMETASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Start: 2022-02-21Target: 134Updated: 2025-02-25